These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22591754)

  • 1. Utilization and cost in clinical practice of darbepoetin alfa and epoetin alfa for anemia concomitant with chemotherapy.
    Berger A; Lord C; Corey-Lisle PK; Williams GR; Oster G
    Clin Ther; 2012 Jun; 34(6):1350-63. PubMed ID: 22591754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of darbepoetin alfa and epoetin alfa in clinical practice in patients with cancer-related anemia.
    Berger A; Edelsberg J; Kallich J; Oster G
    Clin Ther; 2008 Jan; 30(1):206-18. PubMed ID: 18343258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
    Song X; Long SR; Marder WD; Sullivan SD; Kallich J
    Ann Pharmacother; 2009 Jul; 43(7):1203-10. PubMed ID: 19584392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The importance of clinical variables in comparative analyses using propensity-score matching: the case of ESA costs for the treatment of chemotherapy-induced anaemia.
    Polsky D; Eremina D; Hess G; Hill J; Hulnick S; Roumm A; Whyte JL; Kallich J
    Pharmacoeconomics; 2009; 27(9):755-65. PubMed ID: 19757869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use and cost of erythropoiesis-stimulating agents in patients with cancer.
    Daniel G; Hurley D; Whyte JL; Willey V; Wilson M; Kallich J
    Curr Med Res Opin; 2009 Jul; 25(7):1775-84. PubMed ID: 19505205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database.
    Vekeman F; McKenzie RS; Bookhart BK; Laliberté F; Duh MS; Tak Piech C; Lefebvre P
    J Med Econ; 2009 Mar; 12(1):1-8. PubMed ID: 19450059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.
    Nordstrom BL; Luo W; Fraeman K; Whyte JL; Nordyke RJ
    J Manag Care Pharm; 2008; 14(9):858-69. PubMed ID: 19006442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit.
    Brophy GM; Sheehan V; Shapiro MJ; Lottenberg L; Scarlata D; Audhya P;
    Clin Ther; 2008 Dec; 30(12):2324-34. PubMed ID: 19167591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial.
    ; Glaspy J; Vadhan-Raj S; Patel R; Bosserman L; Hu E; Lloyd RE; Boccia RV; Tomita D; Rossi G
    J Clin Oncol; 2006 May; 24(15):2290-7. PubMed ID: 16710026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Propensity score matched assessment of treatment patterns and cost of erythropoiesis stimulating agent treatment in patients with cancer receiving myelosuppressive chemotherapy.
    Tunceli O; Bailey RA; Stephenson JJ; Singer J
    J Oncol Pharm Pract; 2013 Dec; 19(4):305-14. PubMed ID: 23235918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synchronization of administrations of chemotherapy and erythropoiesis-stimulating agents and frequency of associated healthcare visits.
    Hill JW; Shreay S; McGarvey N; De AP; Hess GP; Corey-Lisle PK
    Support Care Cancer; 2013 Nov; 21(11):2957-65. PubMed ID: 23756616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anemia management with darbepoetin-alfa in outpatient hemodialysis patients switched from epoetin-alfa: a community hospital experience.
    Agrawal V; Mukherjee S; Kosuri R; Dumler F
    Am J Ther; 2010; 17(5):469-75. PubMed ID: 19770634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ; Jacobson DR
    Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.
    Forbes CA; Worthy G; Harker J; Kleijnen J; Kutikova L; Zelek L; Van Belle S
    Clin Ther; 2014 Apr; 36(4):594-610. PubMed ID: 24656152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS; Rocconi RP; Kilgore LC; Barnes MN
    Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized comparison of once weekly epoetin alfa to extended schedule epoetin or darbepoetin in chemotherapy-associated anemia.
    Steensma DP; Dakhil SR; Novotny PJ; Sloan JA; Johnson DB; Anderson DM; Mattar BI; Moore DF; Nikcevich D; Loprinzi CL
    Am J Hematol; 2015 Oct; 90(10):877-81. PubMed ID: 26149465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.
    Siegel J; Jorgenson J; Johnson PE; Brophy DF; Comstock T; Feng A; Audhya P
    Am J Health Syst Pharm; 2008 Sep; 65(18):1711-9. PubMed ID: 18768997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimate of maintenance EPO to darbepoetin alfa dose conversion ratio in a hospital-based dialysis patient population.
    Sharma A; Yee J; Gandra SR; Khan I; Petersen J
    Curr Med Res Opin; 2010 Nov; 26(11):2679-87. PubMed ID: 20942616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations.
    Duh MS; Mody SH; Scott McKenzie R; Lefebvre P; Gosselin A; Tak Piech C
    Clin Ther; 2006 Sep; 28(9):1443-50. PubMed ID: 17062316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
    Schwartzberg L; Shiffman R; Tomita D; Stolshek B; Rossi G; Adamson R
    Clin Ther; 2003 Nov; 25(11):2781-96. PubMed ID: 14693304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.